Drugs / GEN-001
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04601402 | Oct 2020 → Jan 2023 | head and neck squamous cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma | Genome & Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05998447 | Sep 2023 → Nov 2024 | biliary tract cancer | Genome & Company | Terminated | No outcome recorded |
| Phase 2 | NCT05419362 | Apr 2022 → Aug 2024 | gastric cancer, gastroesophageal junction adenocarcinoma | Genome & Company | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05079503 | Dec 2021 → Aug 2023 | — | Korean Cancer Study Group | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05419362 ↗ |
| Known as | Lactobacillus lactis | “GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain.” NCT05079503 ↗ |
| Modality | Other / unclassified | “Live Biotherapeutic Product” NCT04601402 ↗ |
| Route | Oral | “capsules taken by mouth” NCT04601402 ↗ |